These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24471188)

  • 1. Analysis of PIK3CA mutations in breast cancer subtypes.
    Arsenic R; Lehmann A; Budczies J; Koch I; Prinzler J; Kleine-Tebbe A; Schewe C; Loibl S; Dietel M; Denkert C
    Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):50-6. PubMed ID: 24471188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
    Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
    Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
    Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
    PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
    Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
    Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutation associates with improved outcome in breast cancer.
    Kalinsky K; Jacks LM; Heguy A; Patil S; Drobnjak M; Bhanot UK; Hedvat CV; Traina TA; Solit D; Gerald W; Moynahan ME
    Clin Cancer Res; 2009 Aug; 15(16):5049-59. PubMed ID: 19671852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
    Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
    Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
    Li SY; Wang W; Li JM; Wang Z; Wen RY; Chen J; Miao XT
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):605-8. PubMed ID: 22325221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
    Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
    Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
    Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
    Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
    Saal LH; Holm K; Maurer M; Memeo L; Su T; Wang X; Yu JS; Malmström PO; Mansukhani M; Enoksson J; Hibshoosh H; Borg A; Parsons R
    Cancer Res; 2005 Apr; 65(7):2554-9. PubMed ID: 15805248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutations in in situ and invasive breast carcinomas.
    Miron A; Varadi M; Carrasco D; Li H; Luongo L; Kim HJ; Park SY; Cho EY; Lewis G; Kehoe S; Iglehart JD; Dillon D; Allred DC; Macconaill L; Gelman R; Polyak K
    Cancer Res; 2010 Jul; 70(14):5674-8. PubMed ID: 20551053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.
    Mangone FR; Bobrovnitchaia IG; Salaorni S; Manuli E; Nagai MA
    Clinics (Sao Paulo); 2012 Nov; 67(11):1285-90. PubMed ID: 23184205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
    Karakas B; Colak D; Kaya N; Ghebeh H; Al-Qasem A; Hendrayani F; Toulimat M; Al-Tweigeri T; Park BH; Aboussekhra A
    Cancer Biol Ther; 2013 Oct; 14(10):888-96. PubMed ID: 23982433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.
    Dirican E; Akkiprik M; Özer A
    Tumour Biol; 2016 Jun; 37(6):7033-45. PubMed ID: 26921096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics of PIK3CA gene mutations in Her2-low breast cancer].
    Pavlenko IA; Povilaitite PE; Makarevich NS; Kaciyaev VY; Petrov AV
    Arkh Patol; 2023; 85(4):5-11. PubMed ID: 37530184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
    Barbareschi M; Buttitta F; Felicioni L; Cotrupi S; Barassi F; Del Grammastro M; Ferro A; Dalla Palma P; Galligioni E; Marchetti A
    Clin Cancer Res; 2007 Oct; 13(20):6064-9. PubMed ID: 17947469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.